Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy.

BMC Nephrol · 2026 · PMC13192010 · PMID 42106625

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantP < 0.01actually significant

All statistical tests were two-sided, with P < 0.05 considered to be a statistically significant difference, and it is considered to be a statistically highly significant difference when P < 0.01.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.